Cabotegravir sodium

Following Pfizer’s exit, Shionogi’s holding increases to 21.7%, with GSK maintaining 78.3% majority share Deal simplifies ViiV Healthcare’s shareholder structure. London, 20 January 2026 – GSK plc (LSE/NYSE: GSK) (“GSK”), and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced that they have reached agreement together with Pfizer Inc. (NYSE: PFE) (“Pfizer”) for the 11.7% economic interest in ViiV Healthcare Limited (“ViiV Healthcare”) currently held by Pfizer to be replaced with an investment by Shionogi. As a result of this transaction, Shionogi will increase its economic interest in ViiV Healthcare to 21.7%. GSK will maintain its 78.3% majority owned economic interest. Shionogi will continue to have one Director position on the ViiV Healthcare Board, and will be represented by Dr John Keller who has been a Director of ViiV Healthcare since 2012. Under the terms of the agreement, ViiV Healthcare will issue new shares to Shionogi for consideration of $2.125 bn and cancel Pfizer’s holding in ViiV Healthcare. Pfizer will receive $1.875 bn and GSK will receive a special dividend of $0.250 bn (payable in GBP). ViiV Healthcare, the global specialist HIV company, is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. David Redfern, Chair of ViiV Healthcare said: “This agreement simplifies ViiV’s shareholder structure and we look forward to continuing our highly successful collaboration with Shionogi to advance ViiV’s pipeline and portfolio of long-acting injectable HIV treatment and prevention medicines. GSK would also like to thank Pfizer for its longstanding partnership in the development of ViiV since its establishment in 2009.” John Keller, Ph.D., Director of the Board, Senior Vice President, R&D Supervisory Unit at Shionogi said: “Shionogi is dedicated to addressing major infectious diseases, with HIV being one of our most important focus areas, as reflected by our role in the discovery of the innovative integrase inhibitors dolutegravir and cabotegravir. Our ongoing HIV research continues to contribute to ViiV’s pipeline through licensing agreements, as is the case for the third-generation integrase inhibitor S-395598/VH 4524184. We are delighted to further deepen our strategic partnership with GSK and ViiV through this agreement, redoubling our commitment and participation in improving the lives of people living with or affected by HIV.” Financial and Regulatory Considerations Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026. On completion, GSK will extinguish the Pfizer put option liability through retained earnings. The liability will be remeasured immediately prior to completion, on the same methodology as at 31 December 2025, with any fair value change in the liability recognised as an adjusting item through other operating income. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com. About Shionogi Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza, and currently markets medicines for infectious diseases and central nervous system disorders. For more information, visit https://www.shionogi.com/global/en. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include, but are not limited to, the completion of the transaction on anticipated terms and timing, including obtaining antitrust and other regulatory approvals and clearances in a timely manner or otherwise, and the satisfaction of other conditions to the completion of the transaction. These risks and uncertainties particularly apply with respect to transaction-related forward-looking statements. GSK and Shionogi disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Shionogi enquiries Website Inquiry Form: https://www.shionogi.com/global/en/contact.html Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q3 Results for 2025. Registered in England & Wales: No. 3888792 Registered Office: 79 New Oxford Street London WC1A 1DG ViiV Press Releases & Company Statements For our corporate press office, email: Rachel Jaikaran OR call +44 7823 523 755 For US-specific media enquiries, email: melinda.x.stubbee@viivhealthcare.com OR call +1 919 491 0831 Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine. If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here. Connect with us ViiV Healthcare 79 New Oxford Street London United Kingdom WC1A 1DG Tel: +44 20 8047 5000 Contact us Terms of use Cookie policy Privacy notice Modern Slavery Statement Sitemap All our locations Our Clinical Trial Register GSK.com Carbon Reduction Plan Corporate ethics and compliance Social Media at ViiV Healthcare

With the third quarter in the books, Gilead Sciences boosted the low end of its annual sales forecast by $100 million and lifted its HIV-specific growth expectations to 5% for the year. For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. This week, Gilead had a chance to share some early returns on the med's market debut after its FDA approval five months ago.Since Yeztugo's U.S. launch in June, the drug has garnered $54 million in sales, Gilead reported on Thursday, with $39 million generated specifically during the third quarter. The company has already secured 75% U.S. payer access for Yeztugo, some three months ahead of its original targeted timeframe of six months post-launch, with 90% expected by the end of the first half of 2026, Gilead said in its third-quarter earnings presentation (PDF). Gilead expects $150 million to come from Yeztugo this year, but Citi analysts call this guidance “conservative,” citing broad update and rapid payer coverage as “hallmarks of a strong launch” that the drug has already demonstrated, the analysts wrote in a note to clients. On the flip side, Mizuho analysts note that the Yeztugo's quarterly haul was a "slight miss." In another factor supporting Yeztugo's quick adoption, updated PrEP recommendations have already poured in from key health bodies across the globe, including the U.S. Centers for Disease Control (CDC) and the World Health Organization, Gilead noted, helping cement Yeztugo’s place as a crucial option in the PrEP arsenal. While Yeztugo may be the most-discussed asset in Gilead’s all-star lineup of HIV meds, combo treatment pill Biktarvy is still the standout earner of the drugmaker's portfolio. HIV gains Of Gilead’s $7.3 billion in third-quarter sales, $5.3 billion came from the company's HIV franchise, with Biktarvy alone pulling in $3.7 billion. As it stands, the drug holds 52% of the U.S. HIV treatment market share, according to the company. And after Gilead inked settlements that prevent generics from launching until 2036, Biktarvy doesn’t appear to be slowing down anytime soon.Both Biktarvy and Yeztugo were preceded by Descovy, Gilead’s older once-daily pill that competes with several other PrEP options. Yet, the older drug locked down a record 45% of the U.S. PrEP market share over the third quarter, according to Gilead, and delivered a 20% year-over-year sales spurt.The higher demand reflected the “incredible momentum” in the PrEP market, driven by growing awareness and increased access, Gilead's chief commercial officer Johanna Mercier explained on a call with investors. The strong showing prompted the company to boost its overall HIV sales growth forecast for the year from 3% to 5%.While one of Gilead’s main goals with the Yeztugo launch is to expand the U.S. PrEP market to PrEP-naïve people, it's also anticipating many users to switch over from once-daily oral meds. As it turns out, switches are coming from “across the board,” including from those previously using GSK’s competing long-acting injectable, Apretude, according to Mercier. The PrEP-naïve user population, meanwhile, will “grow with time,” Mercier said.Yeztugo makes for hefty competition to Apretude given its longer dosing window. Even so, Apretude has been carving out its own share of the PrEP market for years, with GSK reporting £120 million ($157 million) for its product during the third quarter, a 75% increase from the same period last year. The company has long maintained that Yeztugo won’t fully push Apretude out of the market due to unfavorable injection-site reactions reported with Yeztugo, given its status as a subcutaneous injection versus Apretude’s intramuscular administration. Gilead, meanwhile, dismisses the injection site reaction point as a “normal” response to an injectable that can be managed by “short-term ice,” Mercier said. Still, the company made sure to train health practitioners across the country on Yeztugo administration in a mission to reach “every single clinic,” she added.Demonstrating the enormous investor interest in the drug, Mercier fielded questions on Yeztugo for nearly the entire duration of the time that Gilead allotted to Q&A during its third-quarter earnings conference call.  Cell therapy struggles Balancing out the HIV sector’s growth, however, were lower sales of cell therapy products Yescarta and Tecartus. Declines for those drugs—as well as Gilead’s COVID-19 med Veklury—prompted a companywide 2% slide in product sales compared to the same period last year, although total revenue, accounting for royalties and other incomes, increased 3%.The cell therapy sales slowdown has been a running theme for several quarters now, as “competitive headwinds from in- and out-of-class therapies” have stifled the growth of the Gilead meds, Mercier said. During the quarter, Yescarta logged a 10% sales decline, falling to $349 million, while Tecartus sales slipped 15% to $83 million.The company expects these headwinds to carry on in the future, but it has established some 40 approved treatment centers this year and remains “committed to increasing the adoption and utilization of cell therapies,” Mercier said.On the bright side, liver disease med Lizdelvi is becoming a growth star of its own, putting up 35% sequential growth to $105 million. After just over a year since its approval in primary biliary cholangitis, the drug is now the No.1 product for second-line treatment of the liver disease, according to the company.